Swiss mice immunized with formalin-inactivated encephalomyocarditis virus (EMCV) produced antibodies to EMCV and were protected when infected intraperitoneally with EMCV. Administration of a potent sheep anti-mouse interferon-c~/fl (IFN-c~/fl) globulin before reinfection did not alter the vaccine-induced protection. Reinfection was associated with a rapid disappearance of the virus at the site of injection and viraemia was not demonstrable. IFN was not detected in the peritoneum or serum. Furthermore, injection of anti-IFN globulin before, during or after vaccination did not modify the humoral response to vaccination or to reinfection. These results indicate that IFN-e/fl does not play a significant role in the resistance of mice to reinfection with EMCV.
Interferon-~//l Is Not Involved in Resistance of Mice to Reinfection with Encephalomyocarditis Virus
By BRUNO POZZETTO AND ION GRESSER* Laboratoire d 'Oncologie Virale, [nstitut de Recherches Scientifiques sur le Cancer, BP 8, 94802 Villejuif C~dex, France (Accepted 30 March 1984) SUMMARY Swiss mice immunized with formalin-inactivated encephalomyocarditis virus (EMCV) produced antibodies to EMCV and were protected when infected intraperitoneally with EMCV. Administration of a potent sheep anti-mouse interferon-c~/fl (IFN-c~/fl) globulin before reinfection did not alter the vaccine-induced protection. Reinfection was associated with a rapid disappearance of the virus at the site of injection and viraemia was not demonstrable. IFN was not detected in the peritoneum or serum. Furthermore, injection of anti-IFN globulin before, during or after vaccination did not modify the humoral response to vaccination or to reinfection. These results indicate that IFN-e/fl does not play a significant role in the resistance of mice to reinfection with EMCV. The use of antibodies to interferon-e/fl (IFN-e/fl) has amply emphasized the role of this interferon in the natural resistance of mice to primary infection with different viruses (Fauconnier, 1971; Gresser et al., 1976a Gresser et al., , b, 1979 Inglot & Chudzio, 1977; Blank & Murasko, 1981) . In contrast, we are not aware of any study concerning the role of IFN in the host response to viral reinfection. Accordingly, we immunized mice against encephalomyocarditis virus (EMCV) using a formalin-inactivated vaccine and then injected antibody to IFN-c~/fl prior to infection with virulent EMCV. The choice of this experimental model was suggested by the important role of IFN in primary infection with EMCV (Gresser et al., 1976a) , and by the feasibility of producing an effective vaccine against reinfection with EMCV (Frantzen, 1948; Kauffmann & Frantzen, 1948) .
Male or female Swiss mice (4 to 5 weeks old) were used in all experiments. The method of producing an anti-EMCV vaccine was adapted from a previously described procedure (Frantzen, 1948) and consisted of treating EMCV with an equal volume of 1 ~o formalin solution for 18 h at 4 °C. The vaccine was then dialysed for 3 to 4 days against phosphate-buffered saline, sterilized by filtration through a 0.22 gm filter, tested for infectivity on L cells and stored at -70 °C. After three intraperitoneal (i.p.) injections of 0-2 ml of undiluted vaccine at intervals of 3 days, more than 90% of mice were protected against i.p. injections of l0 s LDs0 of virulent EMCV. The techniques used for the titration of EMCV and anti-EMCV antibodies have been described previously (Gresser et al., 1968 (Gresser et al., , 1969 , as have the methods used for the production, purification and assay of potent sheep anti-mouse IFN globulin (Gresser et al., 1976a) .
Whereas administration of anti-IFN globulin enhanced the progression of EMCV disease in non-immune mice, it did not modify the resistance of vaccinated mice to reinfection with EMCV (Fig. 1) . Sera and peritoneal washings from vaccinated mice were tested for the presence of EMCV and IFN at various times (2, 24, 48 and 72 h) after i.p. injection with l0 s LD50 of EMCV. EMCV was recovered from peritoneal washings 2 h after reinfection, but was not demonstrable thereafter. Viraemia was not demonstrable. IFN was not detected at any time in blood (initial dilution 1/10) or in peritoneal washings (initial dilution 1/5). [In order to eliminate residual EMCV, specimens were ultracentrifuged and anti-EMCV hyperimmune serum was added to the supernatant fluids prior to IFN assays. Thus, as the specimens were not passed at an acid pH, our assays should have permitted detection of IFN-%] In contrast, high titres of both 522.8-4125.5 t reinfection * In expt. 1, mice were injected i.p. with 0.2 ml anti-IFN globulin (dilution 1/20 equivalent to 160000 neutralizing units) 2 days before the first vaccination and 1 h after each of the three vaccinations. Mice were vaccinated as described in the text. Antibody titres were measured 7 days after the last immunization. In expt. 2, 1 week after vaccination (as in expt. 1) mice were injected i.p. with 0.2 ml anti-IFN globulin (dilution 1/20) 3 days and 1 h before reinfection i.p. with 0.2 ml l0 s LDs0 of EMCV. Antibody titres were determined 6 days after infection with EMCV.
"~ Not significant using Student's t-test.
EMCV and IFN were demonstrable in non-immune mice in the days following EMCV infection.
In a second series of experiments, we determined the effect of anti-IFN globulin on the humoral response to EMCV. The results presented in Table 1 show that administration of anti-IFN globulin either in the course of vaccination (expt. 1) or just prior to reinfection with EMCV (expt. 2) did not modify the level of the primary (expt, 1) or secondary (expt. 2) antibody response.
We conclude from these results that if endogenous IFN-e/# is induced in the course of reinfection with EMCV, the amounts are small and not demonstrable by the usual biological assays. Moreover, the failure of anti-IFN-c~/# globulin to induce disease in vaccinated mice argues against any role of IFN-c~/# in this experimental model. Thus, in contrast to primary EMCV infection, IFN-~/# is not involved in the resistance to EMCV reinfection which is most likely mediated by humoral antibody.
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